Alcohol addiction, affecting approximately four percent of the population, contributes significantly to the global burden of diseases and is a substantial cost to the society. The neurochemical mechanisms regulating alcohol mediated behaviors is complex and in more recent years a new physiological role of the gut-brain peptides, traditionally known to regulate appetite and food intake, have been suggested. Indeed, regulators of alcohol-mediated behaviors. One of these gut-brain peptides is the annorexigenic peptide glucagon-like peptide-1 (GLP-1), Preclinical studies show that GLP-1 receptor activation, either by GLP-1 or analogues, attenuate the ability of alcohol to activate the mesolimbic dopamine system as well as decrease alcohol consumption and operant self-administration. In further support for the endogenous GLP-1 system in addiction processes are the experimental data showing that a GLP-1 receptor antagonist increases alcohol intake. Moreover, GLP-1 receptor agonists prevent the ability of other addictive drugs to activate the mesolimbic dopamine system. The number of clinical studies is limited, but show i) that genetic variation in the GLP-1 receptor gene is associated with alcohol addiction as well as increased alcohol infusion in humans, ii) that plasma levels of GLP-1 are associated with the subjective experience of cocaine and iii) that a GLP-1 receptor agonist reduces alcohol intake in patients with type-2 diabetes mellitus. These experimental and clinical studies raises the concern that clinically available GLP-1 receptor agonists deserves to be tested as potential treatments of patients with addictive disorders including alcohol addiction.
1. Introduction
Alcohol use disorder
Alcohol use disorder (AUD) is today clearly defined in the latest version of DSM 5 and includes parameters such as loss of control over alcohol intake, impaired cognitive functioning, negative social consequences, physical tolerance, withdrawal and craving for alcohol. Albeit alcohol addiction contributes significantly to the global burden of diseases by causing substantial morbidity and early mortality and affects approximately four percent of the population over the age of 15 (Rehm et al., 2009) , only three medications are approved for the treatment of alcohol addiction in Europe as well as the United States. These are disulfiram (an aldehydedehydrogenase inhibitor), naltrexone (an opioid receptor antagonist) and acamprosate (various targets affected). In addition, nalmefene (an opioid receptor modulator) was recently approved for treatment of AUD in Europe, and clinical studies report a robust reduction in alcohol intake following nalmefene treatment (Serecigni, 2015) . Metanalysis studies have shown that acamprosate and naltrexone causes a similar reduction in return to drinking (Jonas et al., 2014) . It has furthermore been shown that acamprosate foremost promotes abstinence whereas naltrexone reduces heavy drinking as well as craving (Maisel et al., 2013) . Albeit several treatment strategies are available patients with AUD remain greatly undertreated. It should also be noted that patients respond differently to treatments (Heilig and Egli, 2006) , which may depend on the heterogeneous nature of the disorder and the complex neurochemical mechanisms underlying development of alcohol addiction. There is therefore a substantial need for further identify the neurochemical substrates involved in AUD development. Thereby new medications to treat this chronic relapsing psychiatric disorder can be developed.
The mesolimbic dopamine system and alcohol
Serendipitous findings from the 1950s, showing that rats selfadminister electrical currents into few specific brain regions, identified some neuronal circuits involved in reward regulation and these were denominated the mesocorticolimbic dopamine system (Olds and Milner, 1954) . This network of neurons includes dopamine projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc; i.e. the ventral striatum), the prefrontal cortex (PFC) and amygdala (Dahlstrom and Fuxe, 1964; Wise and Rompre, 1989) . Most commonly this pathway is divided into two distinct systems namely the mesolimbic circuit (from the VTA to the NAc) and the mesocortical circuit (from the VTA to the PFC) (Dahlstrom and Fuxe, 1964) . The mesolimbic dopamine system has been implied to modulate incentive salience of motivated behaviors and its activation may be linked to the euphoric effects of rewards, both natural and artificial (see e.g. (Koob, 1992; Robinson and Berridge, 1993; Wise, 1987) ).
Experimental studies have demonstrated that acute alcohol injection (Blomqvist et al., 1993 (Blomqvist et al., , 1997 Di Chiara and Imperato, 1986; Engel et al., 1988; Ericson et al., 1998; Imperato and Di Chiara, 1986; Jerlhag et al., 2006 Jerlhag et al., , 2009 Larsson et al., 2004; Larsson et al., 2002) as well as alcohol consumption (Doyon et al., 2003; Ericson et al., 2003; Larsson et al., 2005; Weiss et al., 1993) activate the mesolimbic dopamine system as shown by an acumbal dopamine release. These initial preclinical studies have due to the development of new imaging techniques been verified in human studies. Indeed, alcohol (Boileau et al., 2003; Urban et al., 2010) as well as other drugs of abuse (Volkow et al., 2004) enhance striatal dopamine release in healthy individuals. The magnitude and rate of ventral striatum dopamine release is closely associated with selfreported behavioral measures of stimulation, euphoria or drug wanting by alcohol (Drevets et al., 2001; Leyton et al., 2002; Ramchandani et al., 2011; Urban et al., 2010; Volkow et al., 1997; Yoder et al., 2007) . Collectively these data suggest that activation of the mesolimbic dopamine system contribute to the alcoholinduced reward and euphoria.
It should however also be emphasized that rewarding properties of alcohol may include indirect as well as direct effects on various neurotransmitters including acetylcholine, glutamate, GABA, serotonin, noradrenaline, glycine and opioids, as well as hormones and peptides (Engel et al., 1988; Ericson et al., 2011; Little, 1999) . Endogenous opioids have been found to modulate the ability of alcohol to induce reward independently as well as dependently on the mesolimbic dopamine system (Jarjour et al., 2009; Pecina, 2008; Serecigni, 2015) . Collectively, this provides some insight into the complex neurocircuits involved in reward, incentive salience and possibly addiction processes, which is most relevant to the scope of the present review. However, a more detailed description of reward and addiction processes falls out of the present scope and is reviewed elsewhere (Gilpin and Koob, 2008; Jarjour et al., 2009; Koob, 2014; Koob and Volkow, 2016; Pecina, 2008; Volkow et al., 2017) .
The link between appetite regulatory peptides and alcoholmediated behaviors
As reviewed elsewhere appetite regulation is complex and involves various circulating hormones produced in the gastrointestinal tract, such as ghrelin, peptide YY 3-36 , oxyntomodulin, cholecystokinin and GLP-1 as well as in adipose tissue e.g. adiponectin, leptin, interleukin-6 and neuropeptides produced in the brain including galanin, orexin and neuropeptide Y (for review see e.g. Fulton, 2010; Zheng et al., 2009) ). These appetite regulatory peptides have through extensive research been shown to regulate homeostatic food intake and appetite via modulation of diverse neurobiological circuits including the hypothalamus (for review see e.g. (Fulton, 2010; Zheng et al., 2009) ). However, several of these gut-brain peptides, including ghrelin, leptin and galanin, have through more recent research been shown to influence mesolimbic dopamine system as well as modulate the ability of alcohol and other addictive drugs to activate this system (for review see e.g. (Engel and Jerlhag, 2014b) ). Experimental studies have also demonstrated that ghrelin receptor antagonist reduces alcohol intake, the motivation to consume alcohol and human studies report that ghrelin enhances craving for alcohol in alcohol-dependent heavy drinkers (for review see e.g. (Engel and Jerlhag, 2014b; Leggio et al., 2014) ). It may therefore be, implied that alcohol consumption and feeding behavior utilize overlapping brain circuitry and mechanisms. One of these more recently discovered common mechanisms is the endocrine hormone GLP-1. The current experimental and clinical knowledge of GLP-1 as a modulator of alcohol and drug-mediated behaviors will be described herein.
1.4. GLP-1 and alcohol mediated behaviors; preclinical studies 1.4.1. GLP-1 attenuates the ability of alcohol to activate the mesolimbic dopamine system as well as reduces alcohol consumption GLP-1 was in 2012 attributed a new physiological function, namely regulation of alcohol-mediated behaviors (Egecioglu et al., 2013c) . This experimental study show that acute treatment with a GLP-1 analogue, exendin 4 (Ex4) attenuated the ability of alcohol to activate the mesolimbic dopamine system as measured by alcoholinduced locomotor stimulation and accumbal dopamine release, in mice (Egecioglu et al., 2013c) . Beyond this, conditioned place preference studies show that injection of Ex4 or liraglutide, another GLP-1 receptor agonist, prior to alcohol during conditioning attenuates expression of the rewarding properties of alcohol in mice (Egecioglu et al., 2013c; Vall€ of et al., 2016) . The ability of Ex4 to block the expression of alcohol-induced conditioned place preference was verified in a follow up study (Shirazi et al., 2013) . Additional experiments demonstrated that acute treatment with Ex4, but not liraglutide, at post-conditioning attenuates the ability of alcohol to cause a reward-dependent memory consolidation as measured in the conditioned place preference model (Egecioglu et al., 2013c; Vall€ of et al., 2016) providing some contradictory results regarding two different GLP-1 receptor agonist. Indeed, Ex4 attenuates both the rewarding properties of alcohol as well as memory formation of reward, whereas liragluitde only modulates the initial expression of reward (Sanchis-Segura and Spanagel, 2006) . This contradicts in some extent previous data showing that liraglutide enhance memory formation, synaptic plasticity as well as hippocampal neuroprotection in a mouse model of Alzheimer disease (Holscher, 2014) . However, the discrepancy in data may be due to different experimental settings and protocol as well as outcomes measured.
Stimulation of GLP-1 receptors has in addition to the ability to regulate alcohol's activation of the mesolimbic dopamine system been found to regulate various alcohol consummatory behaviors. Indeed, acute pharmacological activation of GLP-1 receptors by Ex4 decreases alcohol intake in the intermittent access two-bottlechoice model and prevents alcohol seeking behavior as measured by the progressive ratio test in the operant self-administration model (Egecioglu et al., 2013c) . These data were later collaborated by others showing that acute peripheral administration of Ex4 reduces alcohol intake in rats (Shirazi et al., 2013) . As further support for a contribution of endogenously released GLP-1 in alcoholmediated behaviors are the data showing that blockade of GLP-1 receptors alone resulted in an increased alcohol intake (Shirazi et al., 2013) . This is further substantiated by the fact that peripheral administration of endogenous GLP-1 as well as direct stimulation of the VTA GLP-1 receptors by GLP-1 infusion robustly reduces alcohol intake in rats (Shirazi et al., 2013) .
One clinical limitation with the GLP-1 receptor agonist Ex4 is that its metabolized rapidly and extensively (Deacon et al., 1995) , and therefore has to be administered twice daily to humans. Therefore, clinically available GLP-1 receptor agonist such as liraglutide, which has protracted and maintained biological activity allowing once daily injection (for review see (Holst, 2004) ), may be of better clinical use. It is therefore of interest that preclinical studies demonstrate that acute administration of a low dose of liraglutide suppresses alcohol-induced accumbal dopamine release as well as reduces alcohol intake in rats (Vall€ of et al., 2016) . It was furthermore demonstrated that repeated treatments of liraglutide decreased alcohol intake in outbred rats as well as reduced the motivation to consume alcohol in the operant self-administration paradigm in rats selectively bred to be alcohol-preferring (Vall€ of et al., 2016) . Additional studies have demonstrated that GLP-1 receptor activation alters the drinking pattern of alcohol. Thus, Ex4 reduced alcohol intake by a protracted latency to the first drink of alcohol as well as a reduced number of drinking bouts without affecting total fluid intake, body weight, or locomotor activity (Thomsen et al., 2017) .
Abstinent alcohol dependent patients commonly relapse to severe alcohol consumption and this is contributes significantly to the burden of the disease. Relapse drinking can be studied in rodents by the alcohol deprivation model, where alcohol is reintroduced to rats that have been abstaining from alcohol. It has been shown in both clinical and experimental studies that craving causes this relapse induced increase in alcohol intake (Spanagel, 2000) . Acute liraglutide treatment prevented relapse drinking of alcohol in outbred rats in the alcohol deprivation model (Vall€ of et al., 2016) . In further support for a modulatory role of GLP-1 in relapse drinking are the recent data showing that repeated Ex4 treatment prevented the deprivation-induced increase in alcohol intake in socially housed mice measured with a high-precision automated fluid consumption system (Thomsen et al., 2017) . In further support for a role of GLP-1 in relapse drinking are the data showing that repeated treatment with another GLP-1 receptor agonist (AC3174) selectively reduced escalated drinking exhibited by dependent mice (Suchankova et al., 2015) . Abstinence from repeated heavy alcohol consumption causes withdrawal-induced anxiety symptoms (Sharma et al., 2007) , and this contributes to relapse to alcohol drinking (Roelofs, 1985; Samson and Harris, 1992) . The ability of GLP-1 signaling to regulate withdrawal-induced anxiety as well as tolerance to the anxiolytic effects of alcohol was recently demonstrated by the findings that these effects were attenuated by either liraglutide or by pharmacological inhibition of the enzyme, dipeptidyl-peptidase IV, responsible for degradation of endogenous GLP-1 (Sharma et al., 2014 (Sharma et al., , 2015 . Collectively, these experimental data indicate that GLP-1 receptors modulate relapse drinking.
Of interest is the data demonstrating that following termination of treatment, AC3174 significantly reduced alcohol intake during the first wash out period and only returned to baseline after a second washout test cycle (Suchankova et al., 2015) . This is further substantiated by the findings from high alcohol-preferring rats showing that liraglutide significantly reduced alcohol intake during the washout period compared to controls (Vall€ of et al., 2016) . These two studies indicate that the effects of GLP-1 receptor activation may manifest after chronic treatment. However, additional studies are warranted to investigate this in more detail.
Identification of areas involved in GLP-1 modulated alcoholmediated behaviors
Since the GLP-1 receptor agonists were administered systemically in these initial studies the mechanisms involved in GLP-1 modulated alcohol reinforcement cannot be determined. However, the findings that both Ex4 and liraglutide readily crosses the blood-brain barrier (Hunter and Holscher, 2012; Kastin and Akerstrom, 2003) may suggest that these pharmacological agents could reach deeper brain areas and thereby regulate alcoholmediated behaviors. This is further substantiated by the findings from GLP-1 receptor knockout mice treated with Ex4 demonstrating that alcohol intake requires central GLP-1 receptors (Sirohi et al., 2016) . A modulatory role of mesolimbic GLP-1 receptors for alcohol reward is likely since it has been shown that GLP-1 receptors are expressed throughout the mesolimbic dopamine pathway (Merchenthaler et al., 1999) and that GLP-1 containing neurons in the nucleus tractus solitarius (NTS) project directly to the VTA and NAc (Alhadeff et al., 2012; Alvarez et al., 1996; Merchenthaler et al., 1999) . In support for such a contention are the results demonstrating that these receptors regulate natural rewards. Indeed, both intra-ventral tegmental and -accumbal administration reduces sucrose lever pressing (Alhadeff et al., 2012; Dickson et al., 2012) and reduces food intake (Dossat et al., 2011) . In line are the data showing that direct stimulation of GLP-1 receptors in the VTA by local infusion of either GLP-1 or Ex4, reduced alcohol intake in rats (Shirazi et al., 2013) . Collectively, these data indicating that central, rather than peripheral mechanisms such as nausea or intestinal discomfort, are involved in GLP-1 induced reduction in alcohol intake. It should however be mentioned that the doses used for intra-VTA infusion was high dose reduced water intake (Shirazi et al., 2013) , indicating that the effects on consumption may be unselective and not necessary depend on GLP-1 receptors.
It should also be considered that GLP-1 receptors outside of the mesolimbic dopamine system might contribute to regulation of alcohol-mediated behaviors. GLP-1 receptors in lateral septum regulate the activity of VTA-dopamine neurons, stress-induce drug relapse as well as cocaine-induced behaviors (Harasta et al., 2015; Highfield et al., 2000; Luo et al., 2011) and GLP-1 receptors within the arcurate nucleus regulate weight loss (Secher et al., 2014) , and may thus be potential contributors to regulation of alcohol-mediated behaviors. Another possible indirect pathway through which GLP-1 may regulate alcohol-mediated behavior are GLP-1 receptors within the NTS, which projecting monosynaptically to the VTA and are known to regulate food intake and food reward (Hayes et al., 2009; McMahon and Wellman, 1998; Richard et al., 2015; Tang-Christensen et al., 1996) . Through preclinical as well as clinical research insula has been identified as an important brain area involved in reward and addiction processes (for review see (Heilig et al., 2017) ). The findings that Ex4 reduced food intake as well as attenuated the ability of food pictures to activate insula in obese subjects highlights that the role of GLP-1 receptors in insula for the modulation of alcohol reinforcement should be explored (van Bloemendaal et al., 2014) .
The number of publications identifying the central mechanisms involved in GLP-1's ability to regulate alcohol related behaviors are limited and therefore are additional studies warranted.
Other tentative mechanisms
The GLP-1 system has been identified as a powerfully regulator of food and fluid intake and it should therefore be considered that ingestive behaviors influence the ability of GLP-1 receptor agonist to reduce alcohol intake. However this appears less likely since a recent study showed that Ex4 reduced intravenous alcohol administration, a model reflecting reinforcement as opposed to ingestive behavior, in mice . In further support are the findings that neither GLP-1 receptor agonist tested influences water or total fluid intake in rats (Egecioglu et al., 2013c; Suchankova et al., 2015; Thomsen et al., 2017; Vall€ of et al., 2016) .
Another tentative explanation is that GLP-1 signaling reduced alcohol-mediated behaviors due to altered metabolism of alcohol. Opposed are the findings that acute administration of liraglutide does not influence the blood alcohol concentrations in mice (Vall€ of et al., 2016) .
The possibility that the pharmacological action of GLP-1 reduced alcohol intake by producing nausea or intestinal discomfort should be considered since GLP-1 receptor activation has been shown to induce a condition taste aversion (Kanoski et al., 2012) . However, this appears less likely since GLP-1 receptor agonists only induced nausea at higher doses (Kanoski et al., 2012) . Moreover, neither acute nor repeated liraglutide or Ex4 treatment does not induce a conditioned place aversion in vehicle-paired mice, indicating that the selected doses of GLP-1 receptor agonists do not induce aversion (Egecioglu et al., 2013c; Graham et al., 2013; Vall€ of et al., 2016) . This is further substantiated by the findings that liraglutide does not condition a taste avoidance to saccharine in mice (McKay and Daniels, 2013) . The findings that GLP-1 receptor agonists increase water intake, without confound effects on total fluid intake, suggest that the effects are selective for alcohol and does not involve nausea (Egecioglu et al., 2013c; Vall€ of et al., 2016) . In the liraglutide study demonstrating a reduction of alcohol intake, the dose was slowly increased over time which in accordance with the clinical use to avoid nausea (Vall€ of et al., 2016) .
Another explaination is that GLP-1 receptor agonists, known to reduce food intake and appetite, influence's alcohols caloric value rather than its rewarding properties. However, this appears less likely since GLP-1 receptor ligands attenuate the reinforcing properties of addictive drugs without a caloric content (for references see below; 5. GLP-1 and drug reinforcement; preclinical studies).
GLP-1 and drug reinforcement; preclinical studies
The above-mentioned articles bring attention to a potential activity of GLP-1 in areas classically associated with the incentive salience of alcohol-mediated behaviors. Taken together with the findings that the mesolimbic dopamine system are activated by addictive drugs such as amphetamine, cocaine and nicotine (Engel and Jerlhag, 2014a) , raises the possibility that GLP-1 receptor activation regulate drug-induced reward. This statement was initially supported by the findings that Ex4, at a higher dose with an effect per se on locomotor activity but no effect on anxiety or aversion, prevents the ability of amphetamine to increase the locomotor activity in mice (Erreger et al., 2012) . In accordance are the data showing that pre-treatment of Ex4, at various high doses, during cocaine conditioning prevents the rewarding effects of cocaine in mice as measured by expression of conditioned place preference (Graham et al., 2013) . These initial reports were corroborated by a more extensive study in mice showing that a low dose of Ex4, with no effect per se on locomotor activity nor accumbal dopamine release, attenuated the ability of amphetamine as well as cocaine to activate the mesolimbic dopamine system as measured by locomotor stimulation, accumbal dopamine release as well as the expression of conditioned place preference in mice (Egecioglu et al., 2013b) . Furthermore, GLP-1 receptor stimulation reduces acute and chronic cocaine self-administration and attenuates cocaineinduced hyperlocomotion as well as striatal dopamine elevation in mice (Sorensen et al., 2015) .
Experiments using central GLP-1 receptor knockout mice in combination with peripheral Ex4 treatment show that amphetamine-induced conditioned place preference involves central GLP-1 receptors whereas hedonic feeding behavior requires both central and peripheral GLP-1 receptors (Sirohi et al., 2016) . In further support for central GLP-1 receptors in drug-induced reward are the data showing that central delivery of Ex4 suppresses the induction of phasic dopamine release in NAc core, but not shell, induced by intravenous cocaine (Fortin and Roitman, 2017) .
Based on the well-established effects of accumbal GLP-1 on food reward (Alhadeff et al., 2012; Dickson et al., 2012) and the anatomical distribution of GLP-1 receptors in the brain (Merchenthaler et al., 1999) may suggest that GLP-1 receptors throughout the mesolimbic dopamine system regulate the reinforcing properties of psychostimulant drugs. A role of accumbal GLP-1 receptors was verified by studies showing that systemic Ex4 administration reduce cocaine-induced elevation of striatal c-fos expression in mice (Sorensen et al., 2015) . In addition ventral tegmental GLP-1 receptors may contribute to regulation of druginduced reward. Indeed, intra-VTA infusion of Ex4 attenuated cocaine, but not sucrose, self-administration in rats (Schmidt et al., 2016) . Moreover, AAV-shRNA-mediated knockdown of GLP-1 receptors in the VTA augmented cocaine self-administration (Schmidt et al., 2016) . The possibility that GLP-1 containing neurons in the NTS, project directly to the VTA and NAc (Alhadeff et al., 2012; Alvarez et al., 1996; Merchenthaler et al., 1999) , may also regulate drug related behaviors since GLP-1 and corticosterone in the NTS regulate cocaine self-administration (Schmidt et al., 2016) . However, the role of endogenous GLP-1 in the attenuation of reward-oriented behavior may in all probability involve several brain areas. Indeed, lateral septum which has been shown to have highest GLP-1 receptor gene activity appear to be essential in mediating responses to cocaine as genetic ablation of GLP-1 receptors in dorsal lateral septum, which leads to increased excitability of these cells, caused an attenuation of reduced cocaine-induced locomotor stimulation and conditioned place preference (Harasta et al., 2015) . This initial a study was later supported by the findings that Ex4 prevents the ability of cocaine to increase the dopamine levels in lateral septum (Reddy et al., 2016) . GLP-1 receptor activation enhances the expression of dopamine transporter and reduces the expression of the retrograde messenger 2-arachidonylglycerol as well as the product of its presynaptic degradation, arachidonic acid in lateral septum (Reddy et al., 2016) . Collectively, these data reveal a novel role of GLP-1R in lateral septum, NAc, NTS as well as in VTA in driving the behavioral responses to cocaine.
Albeit smoking is common in today's society and contributes to major diseases, yet mechanisms of nicotine addiction are poorly understood. Given the above-mentioned GLP-1 interactions with alcohol, amphetamine and cocaine it is perhaps not surprising that recent work has explored the potential of GLP-1 receptor activation and the ability of nicotine to activate the mesolimbic dopamine system. It was initially showed that Ex4, at a dose with no effect per se, blocks nicotine-induced locomotor stimulation, accumbal dopamine release as well as the expression of conditioned place preference as well as attenuate nicotine-induced expression of locomotor sensitization in mice (Egecioglu et al., 2013a) . In accordance are the recent data showing that pharmacological inhibition of GLP-1 elimination and stimulation of GLP-1 receptors attenuates consumption of nicotine in mice (Tuesta et al., 2017) . Attempt to identify the neurochemical circuits involved in GLP-1 dependent nicotine reward identified that activation of GLP-1 receptors in the medial habenular -interpeduncular nucleus circuit abolished nicotine-induced reward and decreased nicotine intake, whereas knockdown or pharmacological blockade increases nicotine intake (Tuesta et al., 2017) .
Albeit data from these initial studies have mapped some neurocircuits involved in GLP-1 regulated drug reinforcement there is a substantial need for additional studies pin pointing areas, circuits and neurotransmitters involved in these responses.
GLP-1 and alcohol use disorder; clinical studies
To date available clinical findings regarding GLP-1 signaling as a regulator of alcohol intake in patients with AUD are limited. The first preliminary data supporting this contention show that liraglutide treatment reduced alcohol intake in patients with diabetes mellitus type 2 (Kalra, 2011) . A human genetic study shows evidence that genetic variation in GLP-1 receptor is associated with alcohol addiction in humans (Suchankova et al., 2015) . When splitting the cohort investigated in this study by ancestry an internal replication of these initial findings were demonstrated in both Caucasians and Afro Americans (Suchankova et al., 2015) . The association between alcohol addiction and genetic variation in GLP-1 receptor were also confirmed in an additional independent cohort (Suchankova et al., 2015) . The GLP-1 receptor genotype was also associated with an increased alcohol infusion and enhanced breath alcohol measurement in social drinkers who selfadministered intravenous alcohol (Suchankova et al., 2015) . Moreover, individuals with the GLP-1 receptor genotype display a higher BOLD response in the right globus pallidus in humans when they receive a notification of outcome for high monetary reward (Suchankova et al., 2015) . Collectively, these human genetic studies provide a link between GLP-1 and AUD.
Intravenous cocaine administration to cocaine dependent individuals significantly reduced the serum levels of GLP-1, indicating that endogenous GLP-1 signaling may be involved in addiction processes (Bouhlal et al., 2017) . Further support is provided by the subjective data showing that GLP-1 levels are associated with cocaine-induced increase in heart rate, feeling high and respiratory rate (Bouhlal et al., 2017 ).
In conclusion the existing clinical data regarding GLP-1 and alcohol/drug related behaviors in humans are limited and additional studies are warranted.
GLP-1, alcohol intake and bariatric surgery
Extensive research shows that bariatric surgery, known to increase the plasma levels of GLP-1 (Cummings, 2009) , causes an impressive weight loss (Carlsson et al., 2012) . Population studies, without correlations to plasma levels of gut-brain hormones are inconclusive and show that gastric bypass can reduce, increase or have no effect on alcohol consumption in humans (for review see (Ertelt et al., 2008) ). One publication showed that gastric bypass reduce alcohol intake in both humans and rats and that this reduction was associated to reduced ghrelin and increased GLP-1 plasma levels . However, studies also report robust increase in alcohol intake following bariatric surgery (Hajnal et al., 2012) and these differences in response may be due to different baseline drinking, weight or background. Therefore, the link between bariatric surgery, GLP-1 and alcohol intake needs to be further investigated in detail.
Discussion, GLP-1 as target for treatment of AUD?
Albeit GLP-1 and its receptors are key component of the satiety signaling system, GLP-1 receptor agonists have been approved for the treatment of type-2 diabetes mellitus (for review see (Holst, 2004) ) due to their ability to inhibit gastric emptying (Flint et al., 2001) , stimulate glucose-dependent of insulin secretion (Kreymann et al., 1987) and suppress glucagon release (Orskov et al., 1988) . It is today well-known that GLP-1 regulate various physiological processes and therefore the clinical use of GLP-1 receptor agonists is associated with several aversive effects including nausea, visceral malaise, emetic events and pancreatitis. Another clinical limitation with the present GLP-1 substances is the subcutaneous administration rout. Therefore new per oral GLP-1 receptor agonists with more selective site(s) of action and with less side effects should be developed.
As presented in the present review various GLP-1 receptor agonists or endogenous GLP-1 i) attenuates the ability of alcohol to activate the mesolimbic dopamine system, ii) prevent relapse drinking, iii) reduce alcohol intake and motivation to consume alcohol as well as iv) improve abstinence symptoms in rodents. Moreover, a GLP-1 receptor antagonist increases alcohol intake. It should however be mentioned that the present research field, i.e. GLP-1 and alcohol-mediated behaviors, is young and additional preclinical work defining the neurochemical, cellular and molecular substrates involved in GLP-1 dependent reward regulation should be conducted. In addition, the available clinical studies are limited but show that i) liraglutide reduce alcohol intake in diabetic patients, ii) polymorphism in GLP-1 receptor genes are associated with AUD and that iii) plasma levels of GLP-1 are associated with the subjective response to cocaine. One could therefore argue that endogenous GLP-1 system contributes to the addiction-like phenotype. The need for randomized clinical trials investigating the effects of GLP-1 receptor agonist on alcohol intake in patients with AUD is therefore substantial.
As exemplified by studies with the partial nicotinic acetylcholine receptor agonist, varenicline, animal models reflecting alcoholmediated behaviors may have relevance for the clinical outcome in studies in AUD patients. Indeed, vareniklin prevents the ability of alcohol to activate the mesolimbic dopamine system and reduces alcohol consumption in rodents (Ericson et al., 2009 ) as well as decreases metabolite of alcohol in humans with AUD (Walther et al., 2015) . Therefore future basic and clinical research on GLP-1 and alcohol mediated behaviors may contribute to pinpointing GLP-1 pharmacotherapies for treatment of addictive disorders such as AUD.
